Should I Buy ACHV? ACHV 2026 Analysis

Should You Buy Achieve Life Sciences Inc (ACHV) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

4.480

1 Day change

26.20%

52 Week Range

6.030

Analysis Updated At

2026/04/09

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Achieve Life Sciences Inc (ACHV) does not present a strong buy opportunity for a beginner, long-term investor at this time. While there are positive catalysts, such as the analyst's optimistic view on cytisinicline and its potential approval, the financial performance remains weak, and technical indicators do not signal a clear upward trend. The absence of Intellectia Proprietary Trading Signals further supports a cautious approach.

Technical Analysis

The MACD is positive and expanding, suggesting mild bullish momentum. However, the RSI is neutral at 56.47, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its resistance levels (R1: 3.287, R2: 3.459), which may limit immediate upside potential.

Options Data

Bullish

Open Interest Put-Call Ratio

Neutral

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Analyst from H.C. Wainwright sees the removal of Pfizer's Chantix as a positive for ACHV's cytisinicline, with a Buy rating and a $12 price target. The PDUFA date for cytisinicline approval on June 20 could act as a significant catalyst.

Neutral/Negative Catalysts

EPS dropped by 25% YoY. No recent news or significant insider/hedge fund activity to boost confidence.

Financial Performance

In Q4 2025, the company reported no revenue growth and a net income loss of -$14.66M, though this was an 18.62% YoY improvement. EPS declined by 25% YoY to -0.27, reflecting ongoing financial struggles.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

H.C. Wainwright maintains a Buy rating with a $12 price target, citing the potential for cytisinicline approval as a significant positive for the company.

2 Analyst Rating

Wall Street analysts forecast ACHV stock price to rise

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 3.550

Low

Averages

15.5

High

Current: 3.550

Low

Averages

15.5

High

H.C. Wainwright

maintain

$12

AI Analysis

2026-02-06

Reason

H.C. Wainwright

Price Target

$12

AI Analysis

2026-02-06

maintain

Reason

H.C. Wainwright views Pfizer's (PFE) launch of Chantix among the 30 medicines it placed on the White House's direct-to-consumer site, TrumpRx, as "a significant positive" for Achieve Life Sciences (ACHV) and cytisinicline, arguing that the news removes the potential of Pfizer bringing Chantix back to market and putting any marketing dollars behind the product. The move to include Chantix on TrumpRx is "not random or economically driven," but rather likely a concession to the Make America Healthy Movement within the current administration, which bodes well for the potential for cytisinicline's chances of approval by the current PDUFA date on June 20, adds the analyst, who has a Buy rating and $12 price target on Achieve shares.

JMP

Jason Butler

Outperform

initiated

$19

2025-11-25

Reason

JMP

Jason Butler

Price Target

$19

2025-11-25

initiated

Outperform

Reason

Citizens JMP analyst Jason Butler initiated coverage of Achieve Life Sciences with an Outperform rating and $19 price target. Achieve is developing cytisinicline, a nicotine dependence treatment for smoking cessation in adults, the analyst tells investors in a research note. The firm believes cytisinicline has a "highly differentiated" profile to Chantix and can both supplant and grow the current market.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ACHV

Unlock Now

ACHV Should I Buy

ACHV Should I Buy

Should You Buy Achieve Life Sciences Inc (ACHV) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch